AI MARKET SCANNING

AtaiBeckley Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.45%
MAX GAP RECORD +4.71%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ATAI
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE)
+0.14%
Mar 06, 2026 Earnings Release 2026-03-06 (BEFORE OPEN)
-2.54%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
-1.39%
Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE)
-1.50%
May 14, 2025 Earnings Release 2025-05-14 (UNDETERMINED)
+0.00%
Mar 17, 2025 Earnings Release 2025-03-17 (UNDETERMINED)
+0.00%
Nov 13, 2024 Earnings Release 2024-11-13 (UNDETERMINED)
+0.00%
Aug 13, 2024 Earnings Release 2024-08-13 (BEFORE OPEN)
-1.61%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.0%
Bullish Gaps (4)
Bearish Gaps (4)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ATAI

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗